List of Schrodinger Platform Customers
New York, 10036, NY,
United States
Since 2010, our global team of researchers has been studying Schrodinger Platform customers around the world, aggregating massive amounts of data points that form the basis of our forecast assumptions and perhaps the rise and fall of certain vendors and their products on a quarterly basis.
Each quarter our research team identifies companies that have purchased Schrodinger Platform for Life Science R&D Platforms from public (Press Releases, Customer References, Testimonials, Case Studies and Success Stories) and proprietary sources, including the customer size, industry, location, implementation status, partner involvement, LOB Key Stakeholders and related IT decision-makers contact details.
Companies using Schrodinger Platform for Life Science R&D Platforms include: Novartis, a Switzerland based Life Sciences organisation with 75883 employees and revenues of $51.72 billion, Bristol Myers Squibb, a United States based Life Sciences organisation with 34100 employees and revenues of $48.30 billion, Takeda, a Japan based Life Sciences organisation with 50000 employees and revenues of $30.60 billion and many others.
Contact us if you need a completed and verified list of companies using Schrodinger Platform, including the breakdown by industry (21 Verticals), Geography (Region, Country, State, City), Company Size (Revenue, Employees, Asset) and related IT Decision Makers, Key Stakeholders, business and technology executives responsible for the software purchases.
The Schrodinger Platform customer wins are being incorporated in our Enterprise Applications Buyer Insight and Technographics Customer Database which has over 100 data fields that detail company usage of software systems and their digital transformation initiatives. Apps Run The World wants to become your No. 1 technographic data source!
Apply Filters For Customers
| Logo | Customer | Industry | Empl. | Revenue | Country | Vendor | Application | Category | When | SI | Insight | Insight Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
 |
Bristol Myers Squibb | Life Sciences | 34100 | $48.3B | United States | Schrodinger | Schrodinger Platform | Life Science R&D Platforms | 2020 | n/a | In 2020, Bristol Myers Squibb deployed the Schrodinger Platform as part of a multi-target drug discovery collaboration in the United States. The engagement used the Schrodinger Platform within the Life Science R&D Platforms category to support discovery-stage work aimed at identifying and advancing development candidates across oncology, immunology, and neurology. Implementation centered on computational discovery capabilities typical of Life Science R&D Platforms, including integrated molecular modeling, physics-based simulations, high-throughput virtual screening, and structure-based lead optimization workflows. The Schrodinger Platform was configured to support iterative in silico design and prioritization, enabling discovery teams to triage candidate chemotypes and refine structure activity relationships during early-stage candidate selection. Governance for the program was structured as a collaboration, with Bristol Myers Squibb retaining responsibility for clinical development and commercialization of any resulting candidates. The arrangement announced in 2020 included a $55 million upfront payment from Bristol Myers Squibb to Schrödinger, with additional potential milestone and royalty payments contingent on development and commercial outcomes, and the operational scope focused on BMS research and development functions in the United States. | |
 |
Novartis | Life Sciences | 75883 | $51.7B | Switzerland | Schrodinger | Schrodinger Platform | Life Science R&D Platforms | 2024 | n/a | In 2024, Novartis implemented the Schrodinger Platform across its global research organization to scale computational predictive-modeling and enterprise informatics capabilities. The announcement formalized a multi-target collaboration and expanded software licensing to accelerate candidate identification and design, positioning the Schrodinger Platform as a core toolset within Novartis research workflows. The Schrodinger Platform deployment emphasizes computational predictive-modeling engines and enterprise informatics modules typical of Life Science R&D Platforms, including molecular simulation, structure-based design workflows, modeling pipelines, and centralized data management to support candidate prioritization. Configuration work focused on enabling reproducible simulation workflows and shared modeling libraries to support cross-team discovery activities. Operational coverage extended across Novartis R&D functions globally, embedding the Schrodinger Platform into research chemistry, computational biology, and early discovery workflows to enable collaborative modeling and design work across sites. The implementation scope is enterprise scale within the research organization, enabling standardized workflows and consistent data handling for preclinical candidate evaluation. Contract governance and financial terms were explicit, the agreement included a $150 million upfront license and expanded multi-year software access, and it specified regulatory clearance steps with expected upfront payment timing into early 2025. The arrangement establishes a multi-target collaboration framework to coordinate modeling priorities and license management between Novartis and Schrodinger within R&D. | |
 |
Takeda | Life Sciences | 50000 | $30.6B | Japan | Schrodinger | Schrodinger Platform | Life Science R&D Platforms | 2017 | n/a | In 2017 Takeda began a multi year research collaboration that deployed the Schrodinger Platform as a Life Science R&D Platforms capability for multi target small molecule drug discovery across Takeda's core therapeutic areas in Japan. The collaboration announced Schrodinger leading computational discovery workflows while Takeda supplied structural biology support and governance terms that defined program options and economics. The Schrodinger Platform was applied as a physics based computational platform to support predictive molecular modeling, virtual screening and structure based design workflows typical of Life Science R&D Platforms, aligning computational chemistry and molecular simulation with medicinal chemistry decision making. Implementation emphasis was on integrated discovery pipelines that generated candidate hypotheses for experimental validation, with iterative refinement driven by Takeda structural biology outputs. Operational coverage was focused on Takeda research activities in Japan across multiple therapeutic areas, governed by a multi year multi target research agreement. The collaboration framework included expansion provisions that later increased the number of potential programs and provided Takeda with options to license programs under agreed economic terms. Governance and workflow orchestration positioned Schrodinger to lead discovery execution while Takeda retained experimental validation and licensing decision authority, establishing joint milestones for progression of computational candidates to structural validation and downstream development. The Schrodinger Platform therefore functioned as a central computational engine within Takeda's R&D workflows, connecting in silico candidate generation to Takeda laboratory confirmation and program optioning. |
Buyer Intent: Companies Evaluating Schrodinger Platform
Discover Software Buyers actively Evaluating Enterprise Applications
| Logo | Company | Industry | Employees | Revenue | Country | Evaluated | ||
|---|---|---|---|---|---|---|---|---|
| No data found | ||||||||